NASDAQ OMX

Aegex Technologies Announces Strategy at SPE Offshore Europe 2017 to License Intrinsic Safety Designs and Services to Improve Safety in Oil & Gas Operations

Dela

Calls on Offshore Equipment Manufacturers to Collaborate to Make All Mobile Devices Intrinsically Safe

ABERDEEN, United Kingdom, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Aegex Technologies, the leader in intrinsically safe mobile devices and Internet of Things (IoT) solutions for hazardous area industrial operations, has announced it will license access to its intrinsic safety designs for mobile devices. It will also provide production and testing services to other technology companies serving the oil & gas industry. This strategy leverages Aegex's proprietary intrinsically safe technology to promote collaboration and further innovation in the offshore equipment industry, enabling greater operational safety and efficiency.

Aegex made the announcement today during the SPE Offshore Europe 2017 exhibition, Europe's largest oil & gas exploration and production technology showcase. The company is demonstrating its Aegex10 Intrinsically Safe Tablet and IoT Platform at Stand #2C120 in the event's Technology Zone.

"In the same spirit that the OGTC [The Oil & Gas Technology Centre] here in Aberdeen is aggregating the strengths of technology companies to create new solutions for the offshore industry, Aegex will license and provide other manufacturers access to our intrinsically safe technology, manufacturing facilities and testing grounds," said Aegex CEO Thomas P. Ventulett. "The goal is to make sure every device used in hazardous area operations is the absolute safest possible."

"Intrinsically safe" (IS) devices, such as Aegex's flagship product, the Aegex10 IS Tablet, are certified under international standards for the most potentially explosive conditions, including Zone 1 areas of oil & gas operations. IS devices are designed to limit a concentration of heat or energy that could ignite combustible environments, or "hazardous areas." This is distinct from "explosion-proof" devices, which do not necessarily prevent an explosion but encapsulate it in a protective housing. The benefit of the Aegex design is that equipment is intrinsically safe "from the inside," rather than relying on heavy and expensive explosion-proof form factors.

Aegex will use its proprietary methodologies to assist companies to make offshore solutions intrinsically safe, such as IoT sensors, wearables, accessories, peripherals and scanners that help increase efficiency and safety across operations, from inventory management to equipment maintenance to personnel health.

The new Aegex services include support from the company's research and development division, AegexLabs, which is comprised of an innovation center, engineering and design studio, and manufacturing facilities in Hungary, plus an 800-acre testing facility in the United States, where it tests hazardous area products under realistic conditions.

"Oil and gas operators are increasingly seeking IoT technologies that can help them work more efficiently and more safely. Aegex wants to offer our expertise to other innovators and collectively develop new technologies that can truly reduce costs, increase productivity and enhance safety in offshore industries," Mr. Ventulett added.

Multiple regional and international standards govern the safety and quality of all equipment used in oil & gas operations. These standards - including directives regulated by ATEX, IECEx, UL and other standards bodies - exist to prevent the accidental ignition of combustible atmospheres by an electronic device.

The Aegex10 tablet is globally certified as intrinsically safe for ATEX/IECEx Zone 1 and UL Class I, II, III Division 1 hazardous areas, where flammable materials are likely to be present during normal operations.

About Aegex Technologies
With world headquarters in Atlanta, Ga., USA, European headquarters in Rotterdam, Netherlands, sales offices in Southampton, UK and Dubai, UAE, and distributors worldwide, Aegex provides intrinsically safe mobile and Internet of Things (IoT) solutions for hazardous locations in oil & gas, chemical, pharmaceutical, public safety and other industries with explosive environments.

Contact Aegex for more details. Watch an Aegex overview video to learn more. LinkedIn Twitter Facebook Google+ Instagram

Leigh Villegas
Marketing & Communications Director
+1 229 220 9660
press@aegex.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aegex Technologies via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00Pressmeddelande

AUSTIN, Texas, Sept.  21, 2017  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech

At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58Pressmeddelande

LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service.  As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al

Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00Pressmeddelande

Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00Pressmeddelande

Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea

Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00Pressmeddelande

Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23Pressmeddelande

DANVERS, Mass., Sept.  20, 2017  (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum